E Fund Management Co. Ltd. Grows Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

E Fund Management Co. Ltd. raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,068 shares of the company’s stock after buying an additional 12,776 shares during the period. E Fund Management Co. Ltd. owned about 0.10% of Kymera Therapeutics worth $2,698,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Blue Trust Inc. boosted its position in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the period. Quarry LP purchased a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $95,000. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the period. Thrivent Financial for Lutherans purchased a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $313,000. Finally, Walleye Capital LLC purchased a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $472,000.

Insider Activity

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,788 shares of company stock valued at $455,202 over the last ninety days. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $32.54 on Friday. The firm has a market capitalization of $2.11 billion, a PE ratio of -13.91 and a beta of 2.22. Kymera Therapeutics, Inc. has a 1-year low of $29.07 and a 1-year high of $53.27. The company’s fifty day moving average price is $38.23 and its 200-day moving average price is $43.40.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on KYMR. BMO Capital Markets started coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 target price for the company. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. BTIG Research started coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target for the company. HC Wainwright lifted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.